ABSTRACT

Diffuse large B-cell lymphoma (DLBCL) patients have an excellent prognosis with 60% current 5-year overall survival rate, however, unacceptable large number of patients suffer from relapse or refractory (R/R) disease. Given the clinical diversity among DLBCL patients, there is an urgent need for understanding the molecular heterogeneity of the disease and its influence on patient’s prognosis and the success of treatment as well as developing new treatment strategies based on the molecular defects that underpin resistance to R-CHOP ( bxsucxccro mnm t,itu,iccxmro mtctburxmxio eximbxusxiro cim ,brmixutir )

immunotherapy. The present review introduced the novel genetic classification system for DLBCL, discussed recent experimental genomic studies which employed next generation sequencing techniques aimed for identifying molecular lesions associated with treatment failure in DLBCL patients.

Keywords: DLBCL, R-CHOP, therapy failure, Genomics